Atherothrombotic Adverse Effects of Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia (SOHO 2026) - Sep 1, 2026 - Abstract #CML-1247; Location: LEVEL 3, HALL B3; " The patients were receiving imatinib (26 patients; 16%), nilotinib (50 patients; 31%), dasatinib (26 patients; 16%), bosutinib (4 patients; 3%), ponatinib (44 patients; 28%), asciminib (7 patients; 6%), and vamotinib (2 patients; 1%). In patients with CML, ATAEs are associated with initially high CV risk. Nilotinib and ponatinib demonstrated the most unfavorable toxicity profiles. These findings highlight the importance of CV risk assessment before TKI initiation and its dynamic monitoring during treatment."
Adverse events • Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Nadezhda Shnalieva MD; Darina Zammoeva MD; Olga Kulemina MD; Natalia Lazorko MD; Evgeniya Sbityakova MD; Nadia Siordia MD; Elena Tochenaya MD; Maria Boyarinova MD; Marina Dyshlyk MD; Elena Vasilieva MD; Iurii Osipov MD; Galina Salogub PhD; Elza Lomaia PhD
|